Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose IVIG plus rituximab vs rituximab in kidney transplant patients with de novo donor-specific antibodies
KCT0003923Phase 4Recruiting
- Sponsor
- GC Biopharma
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab, immune globulin in Kidney allograft status (RTx), humoral rejection, sponsored by GC Biopharma. Started Jan 2019; status: recruiting.
02
Drugs
rituximabimmune globulin
03
Conditions
Kidney allograft status (RTx)humoral rejection
Beyond the preview
Go deeper on KCT0003923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003923.